Savara Submits MOLBREEVI BLA for Autoimmune PAP Treatment, Targeting FDA Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Should l Buy SVRA?
Source: Newsfilter
- Exclusive Distribution Agreement: Savara has entered into an exclusive distribution agreement with PANTHERx to ensure the dispensing of MOLBREEVI in the U.S., leveraging PANTHERx's RxARECARE® model to provide personalized patient support services, thereby enhancing patient treatment experience and adherence.
- Biologics License Application: Savara submitted the BLA for MOLBREEVI to the FDA in December 2025, and if granted priority review approval, it will offer a new treatment option for patients with autoimmune pulmonary alveolar proteinosis, significantly improving their quality of life.
- Innovative Drug Development: MOLBREEVI is a recombinant human granulocyte-macrophage colony-stimulating factor delivered via the eFlow® nebulizer system, aimed at restoring macrophage surfactant clearance activity, which is crucial for improving oxygenation and lung function, highlighting its clinical significance.
- Market Potential: Autoimmune pulmonary alveolar proteinosis is a rare and chronic lung disease, and Savara's MOLBREEVI is poised to fill a market gap, addressing the urgent treatment needs of patients and further advancing the company's strategic positioning in the rare disease sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.430
Low
9.00
Averages
10.17
High
11.00
Current: 5.430
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
- FDA Review Progress: Savara has received a Day 74 Letter from the FDA indicating that no Advisory Committee meeting is planned for the MOLBREEVI Biologics License Application (BLA), with ongoing review expected to conclude by the PDUFA target action date of August 22, 2026, laying a solid foundation for market entry.
- EMA Application Submission: The company has submitted the Marketing Authorization Application (MAA) for MOLBREEVI to the European Medicines Agency (EMA) and is on track to submit to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further advancing its European market strategy.
- Therapeutic Potential: MOLBREEVI is positioned as a first-in-class treatment for autoimmune pulmonary alveolar proteinosis (PAP), a rare disease with no approved therapies in the U.S. and Europe, which could fill a significant market gap and meet urgent patient needs if approved.
- Regulatory Recognition: MOLBREEVI has received Fast Track and Breakthrough Therapy Designations from the FDA, as well as Orphan Drug Designation from both the FDA and EMA, highlighting regulatory confidence in its potential efficacy, which may expedite its market launch and enhance competitive positioning.
See More
SAVARA INC AIMS TO FILE MAA WITH UK MHRA BY END OF Q1 2026
Project Submission Timeline: Savara Inc. is on track to submit a New Drug Application (NDA) for its treatment, MaA, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) by the end of the first quarter of 2026.
Regulatory Focus: The submission is part of Savara's ongoing efforts to gain regulatory approval for MaA, which is aimed at addressing specific health needs in the market.
See More
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
- FDA Approval Progress: Savara Inc. has submitted an application for its experimental therapy Molbreevi, with the FDA expected to decide by August 22, 2026, indicating the drug's potential in treating autoimmune pulmonary alveolar proteinosis and possibly significantly improving patient quality of life.
- Fast Track Designation: Molbreevi has received FDA's fast track, breakthrough therapy, and orphan drug designations, which not only expedite the approval process but also enhance investor confidence in the drug's market prospects, leading to a more than 3% rise in Savara's stock in after-hours trading.
- International Application Plans: Savara plans to submit applications to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, demonstrating the company's strategic intent to promote Molbreevi globally and expand market opportunities.
- Market Sentiment Shift: Retail sentiment around SVRA on Stocktwits has shifted from 'neutral' to 'bullish' over the past 24 hours, with message volume remaining high, reflecting investor optimism about the drug, as SVRA stock has more than doubled in the past 12 months, indicating strong market performance.
See More
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
- FDA Review Progress: The U.S. FDA will review Savara's resubmitted BLA for Molbreevi (molgramostim inhalation solution) with priority status, expected to make a decision by August 22, which accelerates the drug's market entry for treating rare lung diseases.
- Drug Background: Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor targeting autoimmune pulmonary alveolar proteinosis, and if approved, it will provide a new treatment option for patients, filling a significant market gap.
- International Application Plans: Savara intends to submit applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of Q1, demonstrating its strategic intent for global market expansion and enhancing its competitiveness internationally.
- Market Reaction: Savara's shares rose approximately 4.5% in after-hours trading on Friday, reflecting investor optimism regarding the FDA's priority review, which may indicate a positive outlook for the drug's future prospects.
See More
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
- FDA Priority Review: Savara announced that the FDA has filed for Priority Review of the BLA for MOLBREEVI, with a PDUFA action date set for August 22, 2026, marking a significant milestone in the treatment of autoimmune pulmonary alveolar proteinosis and potentially offering new options for patients.
- Clinical Data Support: CEO Matt Pauls stated that the substantial data in the application demonstrates that MOLBREEVI improves pulmonary gas transfer and quality of life, which not only enhances the company's reputation in the biopharmaceutical sector but also may drive growth in its market share.
- Multiple Drug Designations: In addition to Priority Review, MOLBREEVI has received Orphan Drug Designation from both the FDA and EMA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA, indicating the drug's potential in treating rare diseases and further strengthening Savara's competitive position.
- Strategic Implications: The development of MOLBREEVI is not only Savara's lead program but could also become the first approved therapy for autoimmune PAP in the U.S. and Europe, with successful commercialization significantly enhancing the company's revenue potential and industry standing.
See More
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
- Priority Review Granted: The FDA has granted Priority Review for Savara's MOLBREEVI application, with a PDUFA action date set for August 22, 2026, marking a significant milestone for the company in the autoimmune PAP treatment space, which could greatly enhance patient quality of life if approved.
- European Application Plans: Savara plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further expanding its international market presence and potentially generating new revenue streams.
- Unique Treatment Potential: MOLBREEVI is poised to become the first approved therapy for autoimmune PAP in both the U.S. and Europe, filling a critical market gap and addressing the urgent need for effective treatments, thereby enhancing Savara's competitive position in the biopharmaceutical industry.
- Clinical Data Support: Savara asserts that the application includes a substantial body of data demonstrating MOLBREEVI's ability to improve pulmonary gas transfer and clinical symptoms, which not only bolsters FDA confidence but also lays a solid foundation for future market promotion.
See More
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
- FDA Review Progress: Savara has received a Day 74 Letter from the FDA indicating that no Advisory Committee meeting is planned for the MOLBREEVI Biologics License Application (BLA), with ongoing review expected to conclude by the PDUFA target action date of August 22, 2026, laying a solid foundation for market entry.
- EMA Application Submission: The company has submitted the Marketing Authorization Application (MAA) for MOLBREEVI to the European Medicines Agency (EMA) and is on track to submit to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further advancing its European market strategy.
- Therapeutic Potential: MOLBREEVI is positioned as a first-in-class treatment for autoimmune pulmonary alveolar proteinosis (PAP), a rare disease with no approved therapies in the U.S. and Europe, which could fill a significant market gap and meet urgent patient needs if approved.
- Regulatory Recognition: MOLBREEVI has received Fast Track and Breakthrough Therapy Designations from the FDA, as well as Orphan Drug Designation from both the FDA and EMA, highlighting regulatory confidence in its potential efficacy, which may expedite its market launch and enhance competitive positioning.
See More
SAVARA INC AIMS TO FILE MAA WITH UK MHRA BY END OF Q1 2026
Project Submission Timeline: Savara Inc. is on track to submit a New Drug Application (NDA) for its treatment, MaA, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) by the end of the first quarter of 2026.
Regulatory Focus: The submission is part of Savara's ongoing efforts to gain regulatory approval for MaA, which is aimed at addressing specific health needs in the market.
See More
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
- FDA Approval Progress: Savara Inc. has submitted an application for its experimental therapy Molbreevi, with the FDA expected to decide by August 22, 2026, indicating the drug's potential in treating autoimmune pulmonary alveolar proteinosis and possibly significantly improving patient quality of life.
- Fast Track Designation: Molbreevi has received FDA's fast track, breakthrough therapy, and orphan drug designations, which not only expedite the approval process but also enhance investor confidence in the drug's market prospects, leading to a more than 3% rise in Savara's stock in after-hours trading.
- International Application Plans: Savara plans to submit applications to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, demonstrating the company's strategic intent to promote Molbreevi globally and expand market opportunities.
- Market Sentiment Shift: Retail sentiment around SVRA on Stocktwits has shifted from 'neutral' to 'bullish' over the past 24 hours, with message volume remaining high, reflecting investor optimism about the drug, as SVRA stock has more than doubled in the past 12 months, indicating strong market performance.
See More
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
- FDA Review Progress: The U.S. FDA will review Savara's resubmitted BLA for Molbreevi (molgramostim inhalation solution) with priority status, expected to make a decision by August 22, which accelerates the drug's market entry for treating rare lung diseases.
- Drug Background: Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor targeting autoimmune pulmonary alveolar proteinosis, and if approved, it will provide a new treatment option for patients, filling a significant market gap.
- International Application Plans: Savara intends to submit applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of Q1, demonstrating its strategic intent for global market expansion and enhancing its competitiveness internationally.
- Market Reaction: Savara's shares rose approximately 4.5% in after-hours trading on Friday, reflecting investor optimism regarding the FDA's priority review, which may indicate a positive outlook for the drug's future prospects.
See More
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
- FDA Priority Review: Savara announced that the FDA has filed for Priority Review of the BLA for MOLBREEVI, with a PDUFA action date set for August 22, 2026, marking a significant milestone in the treatment of autoimmune pulmonary alveolar proteinosis and potentially offering new options for patients.
- Clinical Data Support: CEO Matt Pauls stated that the substantial data in the application demonstrates that MOLBREEVI improves pulmonary gas transfer and quality of life, which not only enhances the company's reputation in the biopharmaceutical sector but also may drive growth in its market share.
- Multiple Drug Designations: In addition to Priority Review, MOLBREEVI has received Orphan Drug Designation from both the FDA and EMA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA, indicating the drug's potential in treating rare diseases and further strengthening Savara's competitive position.
- Strategic Implications: The development of MOLBREEVI is not only Savara's lead program but could also become the first approved therapy for autoimmune PAP in the U.S. and Europe, with successful commercialization significantly enhancing the company's revenue potential and industry standing.
See More
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
- Priority Review Granted: The FDA has granted Priority Review for Savara's MOLBREEVI application, with a PDUFA action date set for August 22, 2026, marking a significant milestone for the company in the autoimmune PAP treatment space, which could greatly enhance patient quality of life if approved.
- European Application Plans: Savara plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further expanding its international market presence and potentially generating new revenue streams.
- Unique Treatment Potential: MOLBREEVI is poised to become the first approved therapy for autoimmune PAP in both the U.S. and Europe, filling a critical market gap and addressing the urgent need for effective treatments, thereby enhancing Savara's competitive position in the biopharmaceutical industry.
- Clinical Data Support: Savara asserts that the application includes a substantial body of data demonstrating MOLBREEVI's ability to improve pulmonary gas transfer and clinical symptoms, which not only bolsters FDA confidence but also lays a solid foundation for future market promotion.
See More
